Sangamo Biosciences, Inc. (SGMO) Posts Q3 EPS Loss of $0.18, Sales Fall Short
Sangamo Biosciences, Inc. (NASDAQ: SGMO) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.82 million.